Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Section 6 of 6

References

162 sources

  1. AAPC (opens in a new tab)
  2. Adebayo et al. (2025) (opens in a new tab)
  3. Adebayo et al. (2026) (opens in a new tab)
  4. Afsar et al. (2025) (opens in a new tab)
  5. AJMC (2026) (opens in a new tab)
  6. Ames et al. (2025) (opens in a new tab)
  7. Arkana Laboratories (opens in a new tab)
  8. Bensink et al. (2024) (opens in a new tab)
  9. Bensink et al. (2026a) (opens in a new tab)
  10. Bensink et al. (2026b) (opens in a new tab)
  11. Blasio et al. (2024) (opens in a new tab)
  12. Canetta et al. (2019) (opens in a new tab)
  13. Chadban et al. (2026) (opens in a new tab)
  14. Chen et al. (2015) (opens in a new tab)
  15. Chen et al. (2017a) (opens in a new tab)
  16. Chen et al. (2017b) (opens in a new tab)
  17. Chen et al. (2021) (opens in a new tab)
  18. Chertow et al. (2024) (opens in a new tab)
  19. Chertow et al. (2025a) (opens in a new tab)
  20. Chertow et al. (2025b) (opens in a new tab)
  21. ClinicalTrials.gov NCT04269031 (opens in a new tab)
  22. ClinicalTrials.gov NCT04340362 (opens in a new tab)
  23. ClinicalTrials.gov NCT04340362 results (opens in a new tab)
  24. ClinicalTrials.gov NCT05312879 (opens in a new tab)
  25. ClinicalTrials.gov NCT05324410 (opens in a new tab)
  26. ClinicalTrials.gov NCT05351047 (opens in a new tab)
  27. ClinicalTrials.gov NCT05865171 (opens in a new tab)
  28. ClinicalTrials.gov NCT05955872 (opens in a new tab)
  29. ClinicalTrials.gov NCT06529796 (opens in a new tab)
  30. ClinicalTrials.gov NCT06794996 (opens in a new tab)
  31. ClinicalTrials.gov NCT06824987 (opens in a new tab)
  32. ClinicalTrials.gov NCT06830629 (opens in a new tab)
  33. ClinicalTrials.gov NCT06839833 (opens in a new tab)
  34. CTIS.eu 2024-515633-15-00 (opens in a new tab)
  35. da Silva Francisco et al. (2024) (opens in a new tab)
  36. Daneshpajouhnejad et al. (2022) (opens in a new tab)
  37. Datta et al. (2024) (opens in a new tab)
  38. Dogra et al. (2026) (opens in a new tab)
  39. Doshi et al. (2018) (opens in a new tab)
  40. Doshi et al. (2024) (opens in a new tab)
  41. Egbuna et al. (2023) (opens in a new tab)
  42. Egbuna et al. (2024) (opens in a new tab)
  43. Elsurer Afsar et al. (2026) (opens in a new tab)
  44. EMA orphan designation EU/3/22/2697 (2022) (opens in a new tab)
  45. EMA paediatric investigation plan EMEA-003368-PIP01-22 (2023) (opens in a new tab)
  46. EMA qualification opinion for GFR slope (2023) (opens in a new tab)
  47. EU Clinical Trials Information System 2024-515633-15-00 (opens in a new tab)
  48. Falk et al. (2022) (opens in a new tab)
  49. FDA FILSPARI prescribing information (2026) (opens in a new tab)
  50. Fierce Biotech (2026) (opens in a new tab)
  51. Foster et al. (2013) (opens in a new tab)
  52. Freedman et al. (2014) (opens in a new tab)
  53. Freedman et al. (2016) (opens in a new tab)
  54. Freedman et al. (2018) (opens in a new tab)
  55. Freedman et al. (2020) (opens in a new tab)
  56. Freedman et al. (2021) (opens in a new tab)
  57. Freedman et al. (2026) (opens in a new tab)
  58. Friedman and Pollak (2021) (opens in a new tab)
  59. Gbadegesin et al. (2023) (opens in a new tab)
  60. Gbadegesin et al. (2025) (opens in a new tab)
  61. Genovese et al. (2010) (opens in a new tab)
  62. Gilbertson et al. (2019) (opens in a new tab)
  63. GlobalData via Pharmaceutical Technology (2024) (opens in a new tab)
  64. Goldschmidt et al. (2024) (opens in a new tab)
  65. Gordon et al. (2018) (opens in a new tab)
  66. Grams et al. (2016) (opens in a new tab)
  67. Grams et al. (2019) (opens in a new tab)
  68. Greensmith et al. (2024) (opens in a new tab)
  69. Gudsoorkar et al. (2020) (opens in a new tab)
  70. Gupta et al. (2023) (opens in a new tab)
  71. Gutiérrez et al. (2018) (opens in a new tab)
  72. Heerspink et al. (2019) (opens in a new tab)
  73. Heerspink et al. (2023) (opens in a new tab)
  74. Heerspink et al. (2026) (opens in a new tab)
  75. Hirth et al. (2026) (opens in a new tab)
  76. Hopper and Olabisi (2024) (opens in a new tab)
  77. Hopper et al. (2026) (opens in a new tab)
  78. Hosey et al. (2026) (opens in a new tab)
  79. Hsu et al. (2026) (opens in a new tab)
  80. Hung et al. (2023) (opens in a new tab)
  81. Inker et al. (2023) (opens in a new tab)
  82. Juliar et al. (2024) (opens in a new tab)
  83. Kalantar-Zadeh et al. (2021) (opens in a new tab)
  84. Kanji et al. (2011) (opens in a new tab)
  85. KDIGO (2021) (opens in a new tab)
  86. KDIGO (2024) (opens in a new tab)
  87. Kopp et al. (2011) (opens in a new tab)
  88. Kopp et al. (2015) (opens in a new tab)
  89. Krissberg et al. (2021) (opens in a new tab)
  90. Ku et al. (2017) (opens in a new tab)
  91. Kudose et al. (2021) (opens in a new tab)
  92. Labcorp (opens in a new tab)
  93. Levey et al. (2020) (opens in a new tab)
  94. Li et al. (2026a) (opens in a new tab)
  95. Li et al. (2026b) (opens in a new tab)
  96. Limb et al. (2024) (opens in a new tab)
  97. Mamak et al. (2026) (opens in a new tab)
  98. Mariani et al. (2025) (opens in a new tab)
  99. Martinelli et al. (2026) (opens in a new tab)
  100. Maze Therapeutics press release, MZE829 phase 2 topline data (2026) (opens in a new tab)
  101. Maze Therapeutics third quarter 2026 results (2026) (opens in a new tab)
  102. McIntosh et al. (2024) (opens in a new tab)
  103. Mohan et al. (2019) (opens in a new tab)
  104. Nadkarni et al. (2017) (opens in a new tab)
  105. Nadkarni et al. (2018) (opens in a new tab)
  106. Nadkarni et al. (2022) (opens in a new tab)
  107. Natera (opens in a new tab)
  108. NCQA (opens in a new tab)
  109. Neuen et al. (2026) (opens in a new tab)
  110. Ojo et al. (2025) (opens in a new tab)
  111. Parsa et al. (2013) (opens in a new tab)
  112. Peralta et al. (2016) (opens in a new tab)
  113. Porter et al. (2016) (opens in a new tab)
  114. Rao et al. (2025) (opens in a new tab)
  115. Reeves-Daniel et al. (2011) (opens in a new tab)
  116. Reidy et al. (2018) (opens in a new tab)
  117. Rheault et al. (2023) (opens in a new tab)
  118. Rodrigue et al. (2016) (opens in a new tab)
  119. Roy et al. (2023) (opens in a new tab)
  120. Sadeghi-Alavijeh et al. (2025) (opens in a new tab)
  121. Soler et al. (2023) (opens in a new tab)
  122. Srinivasan et al. (2025) (opens in a new tab)
  123. Swanepoel et al. (2018) (opens in a new tab)
  124. Szklarzewicz et al. (2025) (opens in a new tab)
  125. Thompson et al. (2019) (opens in a new tab)
  126. Tin et al. (2016) (opens in a new tab)
  127. Travere Therapeutics press release, FILSPARI FSGS approval (2026) (opens in a new tab)
  128. Troost et al. (2018) (opens in a new tab)
  129. Troost et al. (2021) (opens in a new tab)
  130. USRDS Annual Data Report, CKD expenditures (2025) (opens in a new tab)
  131. USRDS Annual Data Report, ESKD incidence and prevalence (2025) (opens in a new tab)
  132. USRDS Annual Data Report, ESRD expenditures (2025) (opens in a new tab)
  133. USRDS Annual Data Report, kidney transplant (2025) (opens in a new tab)
  134. Vertex Pharmaceuticals earnings call transcript (2026) (opens in a new tab)
  135. Vertex Pharmaceuticals first quarter 2026 results (2026) (opens in a new tab)
  136. Vertex Pharmaceuticals Form 10-K (2026) (opens in a new tab)
  137. Vertex Pharmaceuticals Form 10-Q (2026) (opens in a new tab)
  138. Vertex Pharmaceuticals press release, AMKD awareness partnership (2022) (opens in a new tab)
  139. Vertex Pharmaceuticals press release, AMPLIFIED results (2026) (opens in a new tab)
  140. Vertex Pharmaceuticals press release, ASN Kidney Week (2024) (opens in a new tab)
  141. Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022) (opens in a new tab)
  142. Vertex Pharmaceuticals press release, kidney portfolio advancements (2025) (opens in a new tab)
  143. Vertex Pharmaceuticals press release, NEJM publication (2023) (opens in a new tab)
  144. Vertex Pharmaceuticals press release, phase 2 results (2021) (opens in a new tab)
  145. Vertex Pharmaceuticals press release, phase 3 advancement (2024) (opens in a new tab)
  146. Vertex Pharmaceuticals press release, pipeline and business updates (2024) (opens in a new tab)
  147. Vertex Pharmaceuticals press release, pipeline and business updates (2025) (opens in a new tab)
  148. Vertex Pharmaceuticals press release, pipeline and business updates (2026) (opens in a new tab)
  149. Vertex Pharmaceuticals press release, pivotal development (2022) (opens in a new tab)
  150. Vertex Pharmaceuticals second quarter 2026 results (2026) (opens in a new tab)
  151. Vertex Pharmaceuticals third quarter 2026 results (2026) (opens in a new tab)
  152. Vertex Pharmaceuticals VX19-147-101 protocol (2021) (opens in a new tab)
  153. Vertex Pharmaceuticals VX19-147-101 statistical analysis plan (2021) (opens in a new tab)
  154. Wheeler et al. (2022) (opens in a new tab)
  155. WHO Drug Information (2021) (opens in a new tab)
  156. Williams and Ingelfinger (2023) (opens in a new tab)
  157. Wu et al. (2020) (opens in a new tab)
  158. Wyld et al. (2012) (opens in a new tab)
  159. Yee et al. (2026) (opens in a new tab)
  160. Young et al. (2021) (opens in a new tab)
  161. Zimmerman et al. (2021) (opens in a new tab)
  162. Zimmerman et al. (2025) (opens in a new tab)